Turning Point Therapeutics Inc (TPTX) is near the middle in its industry group according to InvestorsObserver. TPTX gets an overall rating of 62. That means it scores higher than 62 percent of stocks. Turning Point Therapeutics Inc gets a 59 rank in the Biotechnology industry. Biotechnology is number 10 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 62 means the stock is more attractive than 62 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Turning Point Therapeutics Inc (TPTX) stock is down -10.92% while the S&P 500 is up 0.05% as of 11:03 AM on Tuesday, May 19. TPTX has fallen -$6.98 from the previous closing price of $63.90 on volume of 950,134 shares. Over the past year the S&P 500 is higher by 4.05% while TPTX is up 56.02%. TPTX lost -$3.49 per share the over the last 12 months.

To screen for more stocks like TPTX click here.

More here:
Is Turning Point Therapeutics Inc (TPTX) a Winner in the Biotechnology Industry? - InvestorsObserver